Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, OGX-011/TV-1011. OGX-011/TV-1011 is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of OGX-011/TV-1011 in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011/TV-1011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance. OncoGenex and Isis partnered in the successful discovery of OGX-011/TV-1011, OGX-427 and OGX-225 and with respect to OGX-011/TV-1011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011/TV-1011 agreement to provide OncoGenex with sole rights to OGX-011/TV-1011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011/TV-1011, OGX-427 and OGX-225 was discovered by the Uni
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 An increase ... ingredients in all forms of food nutrients, regulatory changes ... a substantial rise in demand for natural astaxanthin over ... started to ramp up their capacities to satisfy the ... natural and synthetic source astaxanthin (used in nutraceuticals, aqua ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... , BOTHELL, WA and VANCOUVER, BC, Dec. 20 /PRNewswire-FirstCall/ ... that the Company will host a conference call at 8:30 ... live webcast will be available through the Investor Relations page ... you may access the live conference call by dialing 888-747-4649 ...
... , , KNOXVILLE and ... Knoxville-Oak Ridge Innovation Valley ( www.knoxvilleoakridge.com ) see the successful test ... flight. , The Innovation Valley is home to Oak Ridge National ... itself at the forefront of applied carbon fiber research. ...
... , , NEW ... AOB ), ("the Company" or "AOBO"), a ... and,commercialization of a broad range of prescription and over ... Company,s drugs have been included,in China,s National (Medical) Insurance ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 3American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 2American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 3
(Date:3/18/2015)... Florida , March 18, 2015 ... as businesses, new revolutionary smart wallets and apps continue to ... Companies currently entrenched in the mobile payment industry in focus ... Group Holding Ltd. (NYSE: BABA ), Apple Inc. ... GOOG ) and Facebook Inc. (NASDAQ: FB ) ...
(Date:3/12/2015)... March 12, 2015 IriTech, a leading iris ... of the Texas Instruments Design Network, announced today that ... demonstrated its IriShield USB MK2120U device during a launching ... pension distribution. The iris scanner is ... marketed in India through its ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... an automated literature search tool for the multidisciplinary ... as a free plug-in to Cytoscape 2.1, an ... a visual map of complex biological networks, increasing ... causes of disease. , The Agilent Literature Search ...
... who last year won a Presidential Award, the nation's ... cell research one step closer to reality. , Arinzeh, ... researching the use of stem cells to induce bone ... will not properly heal. She is using adult stem ...
... University in St. Louis have discovered an entirely new ... in plant flowering and DNA methylation, a key chemical ... headed by Craig Pikaard, Ph, D., Washington University professor ... fourth kind of RNA polymerase found only in plants ...
Cached Biology News:Agilent Technologies releases automated literature search tool for biology researchers 2Agilent Technologies releases automated literature search tool for biology researchers 3NJIT Presidential Award winner takes stem cell research another step 2NJIT Presidential Award winner takes stem cell research another step 3New RNA polymerase discovered in plants 2New RNA polymerase discovered in plants 3
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
Biology Products: